The new US UK pharma agreement has reshaped one of the most important trade relationships in global medicine. The UK and the US have reached a deal that will keep tariffs on British pharmaceutical exports at zero for the next three years — a move intended to protect billions in UK medicines shipped to the American market. In exchange, the UK has agreed to raise how much the NHS pays for new treatments, marking the first increase in more than two decades.
Under pressure from President Donald Trump, who had threatened tariffs of up to 100% on branded medicines, the UK negotiated the arrangement to safeguard an export sector worth more than £11bn in the past year. Business and Trade Secretary Peter Kyle said the protection ensures jobs, boosts investment, and strengthens the UK’s position in global life sciences.
Why the US UK Pharma Deal Was Needed
Pharmaceuticals were not initially included in the wave of tariffs the US had announced earlier in the year. However, growing American concerns over dependence on foreign-made medicines, alongside Trump’s repeated claims that US consumers subsidise drug prices elsewhere, raised fears of major trade disruptions.
Under the deal, the UK will raise the NHS price threshold for new medicines by 25% and increase overall drug spending from 0.3% to 0.6% of GDP over 10 years. The rebate scheme requiring pharmaceutical companies to return money to the NHS will also be capped at 15%.
In return, the US guarantees that medicines manufactured in the UK will not face tariff hikes through 2028.
Industry Reaction to the US UK Pharma Agreement
The deal arrives at a critical moment for the UK pharmaceutical landscape. In the past 18 months, several major investments have been paused or withdrawn by companies such as Merck, AstraZeneca, and GSK, as firms shifted large-scale operations toward the US.
Industry groups welcomed the tariff protections. The British Chambers of Commerce called the deal “a real win”, while US-based Bristol Myers Squibb announced plans to invest more than $500m in UK operations.
Still, concerns remain. Analysts warn that rising NHS drug spending could cost the system an extra £3bn. Health experts argue that without new Treasury funding, the added cost could strain already stretched budgets.
With negotiations concluded, both governments say the US UK pharma agreement marks a historic shift toward shared responsibility in drug pricing — and a clearer path for future cooperation in the fast-growing life sciences sector.
